Therapeutic Advances in Psychopharmacology

Scope & Guideline

Advancing the Frontiers of Mental Health Treatment

Introduction

Immerse yourself in the scholarly insights of Therapeutic Advances in Psychopharmacology with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN2045-1253
PublisherSAGE PUBLICATIONS LTD
Support Open AccessYes
CountryUnited States
TypeJournal
Convergefrom 2011 to 2024
AbbreviationTHER ADV PSYCHOPHARM / Ther. Adv. Psychopharm.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND

Aims and Scopes

The journal 'Therapeutic Advances in Psychopharmacology' focuses on advancing the understanding and treatment of mental health disorders through innovative pharmacological approaches, clinical research, and therapeutic strategies. It emphasizes evidence-based practices and the integration of pharmacotherapy in various clinical settings.
  1. Pharmacological Innovations:
    The journal highlights novel pharmacological treatments and therapeutic strategies for various psychiatric disorders, including the use of long-acting injectable antipsychotics, ketamine, and other emerging therapies.
  2. Clinical Outcomes and Effectiveness Studies:
    A significant focus is placed on evaluating the clinical effectiveness of medications and therapeutic interventions, including real-world studies, systematic reviews, and meta-analyses that assess patient outcomes.
  3. Multimorbidity Management:
    The journal addresses the complexities of managing psychiatric disorders in patients with comorbid medical conditions, particularly in older populations, emphasizing integrated care approaches.
  4. Psychedelic Research:
    Research on the therapeutic applications of psychedelics for mental health conditions is a growing area of interest, exploring their potential benefits and safety profiles.
  5. Patient-Centered Outcomes:
    There is a strong emphasis on patient-reported outcomes, adherence to treatment, and the psychosocial aspects of pharmacotherapy, aiming to improve overall patient experiences.
The journal 'Therapeutic Advances in Psychopharmacology' has identified several trending and emerging themes in recent publications, reflecting the evolving landscape of psychopharmacological research and therapeutic approaches.
  1. Psychedelic-Assisted Therapies:
    Research on the therapeutic use of psychedelics, such as psilocybin and ketamine, is gaining momentum, highlighting their potential in treating conditions like depression, PTSD, and anxiety.
  2. Long-Acting Injectable Antipsychotics:
    There is an increasing focus on long-acting injectable antipsychotics, particularly their efficacy and safety in managing schizophrenia and bipolar disorder, as well as their impact on patient adherence and hospitalization rates.
  3. Weight Management in Psychiatric Treatment:
    Studies exploring the management of weight gain associated with antipsychotic medications, including the use of adjunctive treatments like metformin and semaglutide, are becoming more prevalent.
  4. Geriatric Psychiatry:
    The journal is expanding its focus on geriatric psychiatry, addressing the unique challenges and treatment strategies for older adults with mental health disorders, particularly in the context of multimorbidity.
  5. Neurobiological Mechanisms and Biomarkers:
    Research increasingly emphasizes the exploration of neurobiological mechanisms and potential biomarkers for psychiatric disorders, aiming to personalize treatment approaches and improve outcomes.

Declining or Waning

While 'Therapeutic Advances in Psychopharmacology' continues to publish a diverse range of topics, certain themes have shown a decline in prominence over recent years, reflecting shifts in research focus and clinical practice.
  1. Traditional Antidepressants:
    Research on conventional antidepressants appears to be waning, as newer treatments and pharmacological strategies gain traction, indicating a shift towards exploring innovative therapies.
  2. Benzodiazepine Use and Management:
    There has been a noticeable decrease in studies specifically focused on benzodiazepines, possibly due to increased awareness of their risks and a move towards alternative treatment options.
  3. Historical Perspectives on Antipsychotic Medications:
    Discussions centered on historical perspectives or debates regarding antipsychotic medications have diminished, as the field increasingly prioritizes contemporary clinical data and evidence-based practices.
  4. Polypharmacy Issues:
    While polypharmacy remains a pertinent issue, the frequency of dedicated studies addressing this topic has decreased, possibly due to a broader focus on optimizing single-agent therapies.
  5. Case Reports:
    The volume of traditional case reports has declined, as the journal shifts towards more comprehensive studies and trials that provide broader insights into treatment effectiveness.

Similar Journals

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Pioneering Research for Effective Mental Health Solutions
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0268-1315Frequency: 6 issues/year

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, published by Lippincott Williams & Wilkins, stands as a pivotal peer-reviewed journal in the fields of pharmacology and psychiatry. Established in 1986, it has garnered a prominent reputation with a 2023 impact factor placing it in the Q2 category for both Pharmacology and Psychiatry and Mental Health. With an impressive Scopus ranking of #227 in the Psychiatry and Mental Health category and #114 in Pharmacology, it serves as an essential platform for researchers seeking to disseminate critical findings on psychopharmacological interventions and their clinical efficacy. The journal’s rigorous peer-review process ensures that only high-quality research is published, making it a trusted resource for professionals and students alike. By focusing on the latest advancements and evidence-based practices, the INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY contributes significantly to the understanding of mental health treatments, fostering ongoing dialogue and innovation in the discipline.

ADVANCES IN THERAPY

Unveiling the future of medicine through rigorous research.
Publisher: SPRINGERISSN: 0741-238XFrequency: 12 issues/year

ADVANCES IN THERAPY is a prestigious peer-reviewed journal published by SPRINGER, specializing in the diverse fields of medicine and pharmacology. Established in 1984, this influential journal has become an essential resource for researchers and professionals, boasting a commendable impact factor and categorically ranking within the Q1 quartile in both Medicine (Miscellaneous) and Medical Pharmacology as of 2023. With an impressive Scopus ranking at #52 out of 272 in the realm of medical pharmacology, it places itself in the top 81st percentile, underscoring its importance in advancing therapeutic knowledge and practices. Although the journal is not open access, it provides invaluable insights and the latest research findings in therapies that significantly impact patient care, making it a vital reference for clinicians, academicians, and students alike.

JOURNAL OF PSYCHOPHARMACOLOGY

Bridging Research and Practice in Psychopharmacology
Publisher: SAGE PUBLICATIONS LTDISSN: 0269-8811Frequency: 12 issues/year

JOURNAL OF PSYCHOPHARMACOLOGY, published by SAGE Publications Ltd, is a leading peer-reviewed journal that explores the intricate dynamics of pharmacological interventions in mental health and psychiatry. With an ISSN of 0269-8811 and an E-ISSN of 1461-7285, this esteemed journal has established its reputation in the field since its inception in 1987, converging research excellence into 2024. Recognized as a Q1 journal in various categories including Medicine (miscellaneous), Pharmacology, and Psychiatry and Mental Health, it ranks impressively within the top percentile in Scopus, standing at #64 out of 567 in Psychiatry and Mental Health, and #31 out of 272 in Medical Pharmacology. The journal serves as a vital resource for researchers, professionals, and students, providing insightful articles that advance the understanding of psychopharmacological effects and innovations. Although it does not offer open access, the journal's extensive research and impactful findings make it essential reading for anyone engaged in the field. For those seeking to stay at the forefront of psychopharmacology, the JOURNAL OF PSYCHOPHARMACOLOGY is an invaluable asset.

JOURNAL OF CLINICAL PSYCHIATRY

Connecting researchers and clinicians to enhance mental health outcomes.
Publisher: PHYSICIANS POSTGRADUATE PRESSISSN: 0160-6689Frequency: 6 issues/year

The JOURNAL OF CLINICAL PSYCHIATRY is a premier publication dedicated to advancing the understanding and treatment of psychiatric disorders. Established in 1978 and published by Physicians Postgraduate Press, this esteemed journal provides a vital platform for researchers, clinicians, and mental health professionals to share innovative findings and evidence-based practices in psychiatry. With an impressive impact factor and recognized as a Q1 journal in both Medicine (miscellaneous) and Psychiatry and Mental Health, the journal ranks among the top in its field, sitting at 96th out of 567 in Scopus rankings, placing it in the 83rd percentile. The journal's commitment to high-quality, peer-reviewed articles facilitates the dissemination of knowledge crucial for advancing clinical practices and improving patient outcomes. Access to its latest research is offered through institutional subscriptions, making it an essential resource for anyone involved in the mental health sector, from seasoned practitioners to aspiring students.

INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE

Elevating standards in psychiatric research and practice.
Publisher: TAYLOR & FRANCIS LTDISSN: 1365-1501Frequency: 4 issues/year

INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE is a distinguished publication in the field of Psychiatry and Mental Health, published by TAYLOR & FRANCIS LTD in the United Kingdom. With an impressive 2023 impact factor that places it in the Q2 category among its peers, this journal is an essential resource for researchers, clinicians, and students dedicated to advancing mental health practices and understanding psychiatric disorders. Covering topics from clinical studies to innovative treatment methodologies, the journal welcomes original research, reviews, and case studies that contribute valuable insights into clinical practice. Accessible without any open access restrictions, the journal has been a pivotal platform since its inception in 1997, facilitating knowledge exchange in the field up to 2024. As evidenced by its notable Scopus ranking within the top 73rd percentile of Psychiatry and Mental Health, it remains committed to impacting clinical practices significantly.

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Transforming Clinical Practices with Groundbreaking Psychopharmacology Studies
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0271-0749Frequency: 6 issues/year

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, an esteemed publication from Lippincott Williams & Wilkins, serves as a vital resource in the fields of pharmacology and psychiatry. With a notable Q2 ranking in both the medical pharmacology and psychiatry categories, this journal facilitates the dissemination of significant findings related to psychopharmacological research, clinical practices, and advancements in mental health treatment. The journal has been committed to publishing high-quality, peer-reviewed articles since its inception in 1981, covering a wide scope of topics crucial for professionals, researchers, and students alike. With a current impact factor and burgeoning interest from the academic community, the JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY is essential for anyone engaged in the study or practice of clinical psychopharmacology, providing insights that shape contemporary psychiatric medication strategies and improve patient outcomes. For access, please refer to the official publication channels.

REVIEWS IN ENDOCRINE & METABOLIC DISORDERS

Unveiling breakthroughs in metabolism and diabetes.
Publisher: SPRINGERISSN: 1389-9155Frequency: 6 issues/year

REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, published by Springer, is a leading journal in the field of endocrinology, diabetes, and metabolism, with an impressive Q1 ranking in both categories as of 2023. With an ISSN of 1389-9155 and E-ISSN 1573-2606, this journal serves as a vital resource for researchers, clinicians, and students seeking comprehensive reviews that address the latest advancements and interdisciplinary approaches in the management of endocrine and metabolic disorders. Operating from the Netherlands, it features articles that are rigorously peer-reviewed and is notable for its significant impact factor reflected in its Scopus rankings, placing it in the top percentile of its categories. Although it does not currently offer open access, it provides critical insights applicable to both basic and clinical settings, making it indispensable for those dedicated to enhancing patient outcomes in endocrine health.

Psychiatria i Psychologia Kliniczna-JOURNAL OF PSYCHIATRY AND CLINICAL PSYCHOLOGY

Elevating the discourse in psychiatry and clinical psychology.
Publisher: MEDICAL COMMUNICATIONSISSN: 1644-6313Frequency: 4 issues/year

Psychiatria i Psychologia Kliniczna - Journal of Psychiatry and Clinical Psychology is a vital platform for advancing the fields of psychiatry and clinical psychology, published by Medical Communications in Poland. With its ISSN 1644-6313, this Open Access journal has been providing unrestricted access to impactful research since 2005, ensuring that findings in mental health are both accessible and disseminated widely. Although currently ranked in the Q4 quartile across Clinical Psychology and Psychiatry and Mental Health categories, and with the Scopus ranks placing it at 262/311 in Clinical Psychology and 493/567 in Psychiatry, the journal serves as a crucial resource for researchers seeking to explore innovative methodologies and therapeutic interventions. The journal's aim is to enhance understanding and treatment of psychiatric disorders by facilitating the exchange of knowledge between academia and clinical practice. As it converges from 2006 to 2024, Psychiatria i Psychologia Kliniczna remains committed to publishing high-quality articles that contribute toward the evolving landscape of mental health research.

Therapeutic Advances in Neurological Disorders

Transforming understanding into effective therapies for neurological challenges.
Publisher: SAGE PUBLICATIONS LTDISSN: 1756-2856Frequency: 1 issue/year

Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.

Progress in Neurology and Psychiatry

Connecting researchers and clinicians for impactful insights.
Publisher: JOHN WILEY & SONS LTDISSN: 1367-7543Frequency: 4 issues/year

Progress in Neurology and Psychiatry is a pivotal journal published by John Wiley & Sons Ltd, dedicated to advancing the fields of neurology and psychiatry. With a robust history dating back to its establishment, this esteemed journal holds a consistent Q3 ranking in 2023 across several categories including Neurology, Clinical Neurology, Psychiatry, and Mental Health, signifying its significant contribution to the scientific community. This journal serves as a vital source of knowledge and insight, publishing original research, reviews, and case studies that explore the intricacies of neurological and psychiatric disorders. Although it does not offer open access, the journal remains accessible to a wide audience through institutional subscriptions. By fostering a platform for scholarly discourse, Progress in Neurology and Psychiatry aims to bridge the gap between research and practice, ultimately enhancing the quality of care for individuals with neurological and psychiatric conditions. Researchers, clinicians, and students are encouraged to engage with the journal's comprehensive content to stay informed of the latest developments and emerging trends in these critical fields of medicine.